A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity (J2A-MC-GZP1)
Not yet recruiting
- Conditions
- Obesity Overweight
- Registration Number
- jRCT2051250032
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
- Have body mass index (BMI) >=30 kilograms per square meter (kg/m2) or BMI >=25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening:
- hypertension
- dyslipidemia
- obstructive sleep apnea, or
- cardiovascular disease
- Have a history of at least one unsuccessful dietary effort to lose body weight
Exclusion Criteria
- Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
- Have an unstable body weight within 90 days prior to screening
- Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- Have acute or chronic hepatitis or pancreatitis
- Are taking other medications or alternative remedies to manage weight loss
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method - Percent Change from Baseline in Body Weight [ Time Frame: Baseline, Week 40
- Secondary Outcome Measures
Name Time Method